Other highlights in the September 17 issue of JNCI

September 16, 2003

Short PSA Doubling Time Associated with Increased Risk of Death

A prostate-specific antigen doubling time (PSA-DT) of less than 3 months after treatment is associated with an increased risk of death from prostate cancer, according to a new study. Anthony V. D'Amico, M.D., Ph.D., of the Brigham and Women's Hospital in Boston, and his colleagues examined time to prostate cancer-specific mortality among 8,669 patients with localized or locally advanced prostate cancer who were treated with either surgery or radiation therapy. Patients whose PSA levels doubled in less than 3 months had a nearly 20-fold increase in risk of death from prostate cancer and a nearly 7-fold increase in risk of death from any cause. "We recommend that consideration be given to initiating androgen suppression therapy at the time of a PSA-defined recurrence," the authors conclude.

Contact: Amy Dayton, Brigham and Women's Hospital, 617-534-1600, adayton2@partners.org.

Study Examines Risk Factors for Esophageal and Gastric Cancers

A new study suggests that a few risk factors account for a majority of esophageal and gastric cancers in the general population. These factors include smoking, being overweight, having gastroesophageal reflux (acid reflux), and consuming low amounts of fruits and vegetables. The study was conducted by Lawrence S. Engel, Ph.D., now at the Memorial Sloan-Kettering Cancer Center in New York, and his colleagues and involved 1143 patients with esophageal or gastric cancers and 695 healthy controls. "The rapid increase in the incidence of esophageal and gastric cardia adenocarcinomas appears to result from increases in the prevalence of several modifiable and interrelated risk factors," the authors conclude. "Efforts to reduce the prevalence of being overweight, having gastroesophageal reflux, and smoking and to improve diet could reverse this troubling cancer trend."

Contact: Joanne Nicholas, Memorial Sloan-Kettering Cancer Center, 212-639-3573, nicholaj@mskcc.org.

Vitamin E May Play a Role in the Development of Esophageal and Gastric Cancers

High serum levels of á-tocopherol, one of two major forms of vitamin E, are associated with a decreased risk of upper gastrointestinal cancers, a new study has found. Philip R. Taylor, M.D., Sc.D., of the National Cancer Institute, and his colleagues measured serum á- and ã-tocopherol levels in 1,072 patients with esophageal squamous cell carcinoma, gastric cardia cancer, or gastric noncardia cancer, and 1,053 healthy controls. High á-tocopherol levels were associated with a reduced risk of esophageal squamous cell carcinoma, but an increased risk of gastric noncardia cancer. Serum ã-tocopherol levels were not associated with the incidence of any of these cancers.

Contact: NCI Press Office, 301-496-6641, ncipressofficers@mail.nih.gov.

Antisense Inhibition Lowers Incidence of Neuroblastomas in Mice

Inhibition of hMYCN oncogene expression is associated with a reduction in the incidence of neuroblastomas in mice, according to a new study. Neuroblastomas are childhood tumors of sympathetic nervous tissue. Catherine A. Burkhart, and Michelle Haber, Ph.D., of the Children's Cancer Institute Australia for Medical Research, and colleagues used antisense oligonucleotides to inhibit hMYCN expression in mouse models of neuroblastoma. Mice treated continuously with antisense oligonucleotides had a lower incidence of neuroblastomas and lower mean tumor mass than mice treated with control oligonucleotides. "Our results raise the possibility that hMYCN antisense therapy may ultimately be clinically useful in the treatment of childhood neuroblastoma," the authors conclude.

Researchers Address Questions about the Design of Dual-Label Microarrays

The rapid growth in the use of dual-label microarrays for measuring gene expression has generated many questions about how to design experiments that use this technology effectively. In a commentary, Kevin Dobbin, Ph.D., of the National Cancer Institute, discusses common methodologic questions that arise in designing dual-label microarray experiments and provides statistical answers to these questions, with a particular focus on how to select optimal designs for efficient identification of differentially expressed genes. The authors provide detailed examples of the statistical properties of different design options and their robustness, and they discuss the statistical issues related to sample selection, allocation and pooling of samples, pairing of samples for co-hybridization, changes in class definition, class discovery experiments, dye bias, and sample size.

Contact: NCI Press Office, 301-496-6641, ncipressofficers@mail.nih.gov.
Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage.

Journal of the National Cancer Institute

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.